SA
TEVA icon

Shilanski & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Shilanski & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,115
Closed -$170K – 132
2025
Q2 		$170K Sell
10,115
-133
-1% -$2.15K 0.05% 108
2025
Q1 		$158K Buy
10,248
+459
+5% +$8.2K 0.05% 104
2024
Q4 		$216K Buy
+9,789
New +$178K 0.07% 98

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Shilanski & Associates's TEVA Position: Q3 2025 in Review

Shilanski & Associates sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 10,115 shares — an estimated $170K sold.

Shilanski & Associates first reported a position in TEVA in Q4 2024 and held it in 3 quarters. The position peaked at $216K in Q4 2024. 551 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Shilanski & Associates reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Shilanski & Associates sold 10,115 Teva Pharmaceuticals shares in Q3 2025, an estimated $170K.
  • Shilanski & Associates first reported a position in Teva Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Shilanski & Associates's Teva Pharmaceuticals position peaked at $216K in Q4 2024.
  • 551 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.